|
US7045313B1
(en)
|
1982-11-30 |
2006-05-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
|
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
US5443964A
(en)
|
1987-08-10 |
1995-08-22 |
Duke University |
Poxvirus insertion/expression vector
|
|
US6218525B1
(en)
|
1988-02-25 |
2001-04-17 |
The General Hospital Corporation |
Nucleic acid encoding CD28
|
|
US5716826A
(en)
|
1988-03-21 |
1998-02-10 |
Chiron Viagene, Inc. |
Recombinant retroviruses
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
|
DK0584266T3
(da)
|
1991-05-06 |
2003-12-29 |
Us Gov Health & Human Serv |
Rekombinant virus udtrykkende carcinoembryonalt antigen og fremgangsmåder til anvendelse heraf
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
US6887471B1
(en)
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
|
US5262522A
(en)
|
1991-11-22 |
1993-11-16 |
Immunex Corporation |
Receptor for oncostatin M and leukemia inhibitory factor
|
|
MD1367C2
(ro)
|
1992-11-13 |
2000-11-30 |
Idec Pharmaceuticals Corporation |
Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
|
|
US5773253A
(en)
|
1993-01-22 |
1998-06-30 |
Bristol-Myers Squibb Company |
MYPPPY variants of CTL A4 and uses thereof
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
US5457035A
(en)
|
1993-07-23 |
1995-10-10 |
Immunex Corporation |
Cytokine which is a ligand for OX40
|
|
US20020159979A1
(en)
|
1994-06-06 |
2002-10-31 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
|
JP4418965B2
(ja)
|
1994-09-23 |
2010-02-24 |
タップイミューン・インコーポレイテッド |
内在性ペプチドを有するｍｈｃクラスｉ分子の発現を増強する方法
|
|
JP3907698B2
(ja)
|
1994-10-03 |
2007-04-18 |
アメリカ合衆国 |
抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物
|
|
US5998205A
(en)
|
1994-11-28 |
1999-12-07 |
Genetic Therapy, Inc. |
Vectors for tissue-specific replication
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US7153510B1
(en)
|
1995-05-04 |
2006-12-26 |
Yale University |
Recombinant vesiculoviruses and their uses
|
|
US5780426A
(en)
|
1995-06-07 |
1998-07-14 |
Ixsys, Incorporated |
Fivemer cyclic peptide inhibitors of diseases involving αv β3
|
|
US5767071A
(en)
|
1995-06-07 |
1998-06-16 |
Ixsys Incorporated |
Sevenmer cyclic peptide inhibitors of diseases involving αv β3
|
|
FR2735789B1
(fr)
|
1995-06-23 |
1997-07-25 |
Centre Nat Rech Scient |
Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
|
|
EP1983057A3
(en)
|
1995-09-08 |
2009-01-07 |
Genzyme Corporation |
Improved AAV vectors for gene therapy
|
|
US7001765B2
(en)
|
1996-03-06 |
2006-02-21 |
Medigene Ag |
Adeno-associated virus vector for boosting immunogenicity of cells
|
|
US6294170B1
(en)
|
1997-08-08 |
2001-09-25 |
Amgen Inc. |
Composition and method for treating inflammatory diseases
|
|
JP4213224B2
(ja)
|
1997-05-02 |
2009-01-21 |
ジェネンテック，インコーポレーテッド |
ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
|
|
US6165476A
(en)
|
1997-07-10 |
2000-12-26 |
Beth Israel Deaconess Medical Center |
Fusion proteins with an immunoglobulin hinge region linker
|
|
US5891432A
(en)
|
1997-07-29 |
1999-04-06 |
The Immune Response Corporation |
Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
|
|
US6635472B1
(en)
|
1997-08-15 |
2003-10-21 |
Rubicon Laboratory, Inc. |
Retrovirus and viral vectors
|
|
CA2304168A1
(en)
|
1997-09-19 |
1999-04-01 |
The Trustees Of The University Of Pennsylvania |
Methods and cell line useful for production of recombinant adeno-associated viruses
|
|
GB9801930D0
(en)
|
1998-01-29 |
1998-03-25 |
Univ London |
Mutant herpes simplex viruses and uses thereof
|
|
ES2292236T3
(es)
|
1998-04-02 |
2008-03-01 |
Genentech, Inc. |
Variantes de anticuerpos y sus fragmentos.
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6436392B1
(en)
|
1998-05-20 |
2002-08-20 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors
|
|
US20040063094A1
(en)
|
1998-05-20 |
2004-04-01 |
Biovex Limited |
Mutant herpes simplex viruses and uses thereof
|
|
GB2337755B
(en)
|
1998-05-29 |
2003-10-29 |
Secr Defence |
Virus vaccine
|
|
DK2272859T3
(en)
|
1998-08-07 |
2015-01-19 |
Univ Washington |
Immunological herpes simplex virus antigens and methods for their use
|
|
ES2340230T3
(es)
|
1998-11-10 |
2010-05-31 |
University Of North Carolina At Chapel Hill |
Vectores viricos y sus procedimientos de preparacion y administracion.
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
HU230769B1
(hu)
|
1999-01-15 |
2018-03-28 |
Genentech Inc. |
Módosított effektor-funkciójú polipeptid-változatok
|
|
GB9904582D0
(en)
|
1999-02-26 |
1999-04-21 |
Nycomed Imaging As |
Process
|
|
US6428968B1
(en)
|
1999-03-15 |
2002-08-06 |
The Trustees Of The University Of Pennsylvania |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
|
DE19933288A1
(de)
|
1999-07-15 |
2001-01-18 |
Medigene Ag |
Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
|
|
US6365619B1
(en)
|
1999-07-22 |
2002-04-02 |
Novartis Ag |
Treatment of arteriosclerosis
|
|
PT1916258E
(pt)
|
1999-08-09 |
2014-07-29 |
Genzyme Corp |
Aumento da expressão de uma sequência nucleotídica heteróloga de cadeia simples a partir de vectores virais recombinantes por concepção da sequência de maneira que esta forme pares de bases intracadeia
|
|
US7241447B1
(en)
|
1999-10-07 |
2007-07-10 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors and uses thereof
|
|
US7329728B1
(en)
|
1999-10-25 |
2008-02-12 |
The Scripps Research Institute |
Ligand activated transcriptional regulator proteins
|
|
US6723316B2
(en)
|
1999-12-22 |
2004-04-20 |
Onyx Pharmaceuticals, Inc. |
Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth
|
|
DE60115600T2
(de)
|
2000-01-21 |
2006-07-20 |
Biovex Ltd. |
Virusstämme für die onkolytische behandlung von krebs
|
|
US7306902B2
(en)
|
2002-06-28 |
2007-12-11 |
Oncolyties Biotech Inc. |
Oncolytic viruses as phenotyping agents for neoplasms
|
|
EP3029062A1
(en)
|
2000-05-26 |
2016-06-08 |
Bristol-Myers Squibb Company |
Soluble ctla4 mutant molecules and uses thereof
|
|
CA2411828A1
(en)
|
2000-06-23 |
2002-01-03 |
Maxygen, Inc. |
Novel co-stimulatory molecules
|
|
US7183376B2
(en)
|
2000-06-23 |
2007-02-27 |
Maxygen, Inc. |
Variant B7 co-stimulatory molecules
|
|
WO2004029197A2
(en)
|
2001-06-22 |
2004-04-08 |
Maxygen, Inc. |
Co-stimulatory molecules
|
|
US7011972B2
(en)
|
2000-07-18 |
2006-03-14 |
The Scripps Research Institute |
Fusion polypeptide comprising two ligand binding domains
|
|
ATE332398T1
(de)
|
2000-08-11 |
2006-07-15 |
Univ Utah Res Found |
Einfach markierte oligonukleotidsonden
|
|
US6653103B2
(en)
|
2001-03-30 |
2003-11-25 |
Wisconsin Alumni Research Foundation |
Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
|
|
EP1385466B1
(en)
|
2001-05-11 |
2011-03-09 |
Wellstat Biologics Corporation |
Oncolytic virus therapy
|
|
EP1406653A4
(en)
|
2001-06-29 |
2005-05-04 |
Univ Leland Stanford Junior |
T CELL REGULATION GENES AND METHOD OF USE THEREOF
|
|
US20030044386A1
(en)
|
2001-07-11 |
2003-03-06 |
Barber Glen N. |
Recombinant VSV for the treatment of tumor cells
|
|
CN1304559C
(zh)
|
2001-10-09 |
2007-03-14 |
杭州康科生物技术有限公司 |
表达热休克蛋白的溶瘤微生物及其应用
|
|
WO2003042402A2
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
|
US7247615B2
(en)
|
2001-11-30 |
2007-07-24 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Peptide agonists of prostate-specific antigen and uses therefor
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
AU2003258060B2
(en)
|
2002-03-27 |
2007-07-12 |
Baylor College Of Medicine |
Potent oncolytic herpes simplex virus for cancer therapy
|
|
US20030225260A1
(en)
|
2002-04-30 |
2003-12-04 |
Snyder Richard O. |
Production of recombinant AAV virions
|
|
NZ537255A
(en)
|
2002-06-21 |
2009-04-30 |
Wellstat Biologics Corp |
Administration of therapeutic viruses
|
|
EP1391213A1
(en)
|
2002-08-21 |
2004-02-25 |
Boehringer Ingelheim International GmbH |
Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
|
|
JP2005537802A
(ja)
|
2002-09-09 |
2005-12-15 |
ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション |
ラブドウイルスの組み換え型変異体及びその使用方法
|
|
MXPA05003395A
(es)
|
2002-10-03 |
2005-06-22 |
Wyeth Corp |
Polipeptidos de virus de papiloma humano y composiciones inmunogenas.
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
EP3263596A1
(en)
|
2002-12-16 |
2018-01-03 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
|
US7731974B2
(en)
|
2003-03-27 |
2010-06-08 |
Ottawa Hospital Research Institute |
Mutant vesicular stomatitis viruses and uses thereof
|
|
DE602004018284D1
(de)
|
2003-03-27 |
2009-01-22 |
Ottawa Health Research Inst |
Mutante vesicular stomatitis viren und deren verwendungen
|
|
EP1644492B1
(en)
|
2003-06-18 |
2009-01-07 |
Genelux Corporation |
Modified recombinant vaccinia viruses, uses thereof
|
|
CN1856576B
(zh)
|
2003-09-30 |
2011-05-04 |
宾夕法尼亚州立大学托管会 |
腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
|
|
GB0326798D0
(en)
|
2003-11-17 |
2003-12-24 |
Crusade Lab Ltd |
Methods for generating mutant virus
|
|
US7897146B2
(en)
|
2003-11-17 |
2011-03-01 |
Crusade Laboratories Limited |
Treatment using herpes simplex virus
|
|
WO2005049846A2
(en)
|
2003-11-17 |
2005-06-02 |
Crusade Laboratories Limited |
Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
|
|
KR100956913B1
(ko)
|
2003-12-19 |
2010-05-11 |
제넨테크, 인크. |
치료제로서 유용한 일가 항체 단편
|
|
KR100891620B1
(ko)
|
2004-04-13 |
2009-04-02 |
에프. 호프만-라 로슈 아게 |
항-ｐ-셀렉틴 항체
|
|
WO2005116224A2
(en)
|
2004-05-18 |
2005-12-08 |
Children's Memorial Hospital |
Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
|
|
US7427396B2
(en)
|
2004-06-03 |
2008-09-23 |
Genzyme Corporation |
AAV vectors for gene delivery to the lung
|
|
US7731952B2
(en)
|
2004-06-24 |
2010-06-08 |
New York University |
Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
|
|
CN103172731A
(zh)
|
2004-07-15 |
2013-06-26 |
赞科股份有限公司 |
优化的Fc变体
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
US8911726B2
(en)
|
2004-09-22 |
2014-12-16 |
Kyowa Hakko Kirin Co., Ltd |
Stabilized human Igg4 antibodies
|
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
|
WO2006060314A2
(en)
|
2004-12-01 |
2006-06-08 |
Bayer Schering Pharma Aktiengesellschaft |
Generation of replication competent viruses for therapeutic use
|
|
EP3050963B1
(en)
|
2005-03-31 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
|
AU2006252406B2
(en)
|
2005-06-01 |
2012-05-17 |
California Institute Of Technology |
Method of targeted gene delivery using viral vectors
|
|
CN101495126B
(zh)
|
2005-06-23 |
2016-01-06 |
休斯顿大学 |
Ⅱ型单纯疱疹病毒突变体在治疗癌症中的用途
|
|
US7943374B2
(en)
|
2005-08-21 |
2011-05-17 |
Markus Hildinger |
Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
|
|
GB0522476D0
(en)
|
2005-11-03 |
2005-12-14 |
Biovex Ltd |
Oncolytic herpes virus vectors
|
|
BRPI0714495B8
(pt)
|
2006-07-21 |
2021-05-25 |
California Inst Of Techn |
lentivírus deficiente para replicação recombinante pseudotipado
|
|
EP2426142A3
(en)
|
2006-10-16 |
2012-06-13 |
Genelux Corporation |
Modified vaccinia virus strains for use in a diagnostic and therapeutic method
|
|
GB0620934D0
(en)
|
2006-10-20 |
2006-11-29 |
Cambridge Antibody Tech |
Protein variants
|
|
WO2008140621A2
(en)
|
2006-12-21 |
2008-11-20 |
Mount Sinai School Of Medicine Of New York University |
Transgenic oncolytic viruses and uses thereof
|
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
|
EP2114420B1
(en)
|
2007-02-16 |
2016-01-27 |
Virttu Biologics Limited |
Herpes simplex viruses and methods of viral replication
|
|
CA2682527C
(en)
|
2007-03-30 |
2017-07-11 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
|
|
JP5213075B2
(ja)
|
2007-06-15 |
2013-06-19 |
ジェネラックス・コーポレイション |
腫瘍の画像化および／または処置のための微生物
|
|
ATE502114T1
(de)
|
2007-06-21 |
2011-04-15 |
Univ Muenchen Tech |
Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
|
|
EP2170946A2
(en)
|
2007-07-13 |
2010-04-07 |
The Johns Hopkins University |
B7-dc variants
|
|
WO2009011924A1
(en)
|
2007-07-18 |
2009-01-22 |
Genelux Corporation |
Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
|
|
US20090136917A1
(en)
|
2007-10-25 |
2009-05-28 |
Szalay Aladar A |
Systems and methods for viral therapy
|
|
CN101925612A
(zh)
|
2007-11-27 |
2010-12-22 |
维文蒂阿生物技术公司 |
针对癌相关的nfkbib变体的表位的抗体及其用途
|
|
RS56844B1
(sr)
|
2007-12-11 |
2018-04-30 |
Univ North Carolina Chapel Hill |
Retrovirusni vektori sa modifikovanim polipurinskim nizom
|
|
US11260133B2
(en)
|
2008-02-21 |
2022-03-01 |
Sanford-Burnham Medical Research Institute |
Methods and compositions related to peptides and proteins with C-terminal elements
|
|
US8313896B2
(en)
|
2008-04-04 |
2012-11-20 |
The General Hospital Corporation |
Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
|
|
WO2009139921A2
(en)
|
2008-05-16 |
2009-11-19 |
Genelux Corporation |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
|
EP2307033A4
(en)
|
2008-05-29 |
2012-06-13 |
Gen Hospital Corp |
USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
US9283184B2
(en)
|
2008-11-24 |
2016-03-15 |
Massachusetts Institute Of Technology |
Methods and compositions for localized agent delivery
|
|
US8481297B2
(en)
|
2009-01-08 |
2013-07-09 |
Yale University |
Compositions and methods of use of an oncolytic vesicular stomatitis virus
|
|
US20150359909A1
(en)
|
2009-07-16 |
2015-12-17 |
University College Cork-National University Of Ireland, Cork |
Orally administered bacteria as vehicles for systemic delivery of agents
|
|
EP2283810A1
(en)
|
2009-07-16 |
2011-02-16 |
University College Cork-National University of Ireland, Cork |
Orally administered bacteria as vehicles for systemic delivery of agents
|
|
ES2455544T5
(es)
|
2009-07-24 |
2017-08-16 |
Immune Design Corp |
Vectores de lentivirus pseudotipificados con una glucoproteína de envoltura de virus sindbis
|
|
ES2666152T3
(es)
|
2009-08-13 |
2018-05-03 |
The Johns Hopkins University |
Métodos de modulación de la función inmunitaria con anticuerpos anti-B7-H7CR
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
PL3053932T3
(pl)
|
2010-02-19 |
2021-03-08 |
Xencor, Inc. |
Nowe immunoadhezyny CTLA4-IG
|
|
CN106432474A
(zh)
|
2010-03-12 |
2017-02-22 |
艾伯维生物医疗股份有限公司 |
Ctla4蛋白和其用途
|
|
CN102946906B
(zh)
|
2010-04-23 |
2015-07-15 |
弗·哈夫曼-拉罗切有限公司 |
生产异源多聚体蛋白质
|
|
CN103261217B
(zh)
|
2010-11-11 |
2017-04-26 |
港大科桥有限公司 |
可溶性 pd‑1变体、融合构建体及其用途
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
EP2686345B1
(en)
|
2011-03-16 |
2018-04-25 |
Amgen Inc. |
Fc variants
|
|
WO2012141984A1
(en)
|
2011-04-08 |
2012-10-18 |
Immune Design Corp. |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
|
RS55609B1
(sr)
|
2011-04-13 |
2017-06-30 |
Bristol Myers Squibb Co |
Fc fuzioni proteini koji sadrže nove linkere ili aranžmane
|
|
WO2012149364A1
(en)
|
2011-04-28 |
2012-11-01 |
Diamond Don J |
Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
|
|
TWI496886B
(zh)
|
2011-06-24 |
2015-08-21 |
Taipei Veteran General Hospital |
提升感染性與惡性疾病之治療之免疫反應
|
|
MY180616A
(en)
|
2011-06-30 |
2020-12-03 |
Genzyme Corp |
Inhibitors of t-cell activation
|
|
US8956619B2
(en)
|
2011-10-25 |
2015-02-17 |
University Of Maryland, Baltimore County |
Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
|
|
HRP20201595T1
(hr)
|
2011-11-28 |
2020-12-11 |
Merck Patent Gmbh |
Anti-pd-l1 protutijela i njihova uporaba
|
|
CN117462693A
(zh)
|
2012-02-27 |
2024-01-30 |
阿穆尼克斯运营公司 |
Xten缀合组合物和制造其的方法
|
|
PT2831095T
(pt)
|
2012-03-30 |
2019-01-30 |
Immune Design Corp |
Partículas de vectores lentivirais com melhor eficácia de transdução de células que expressam dc-sign
|
|
JP6228971B2
(ja)
|
2012-05-11 |
2017-11-08 |
メディミューン，エルエルシー |
Ｃｔｌａ−４バリアント
|
|
JP5857896B2
(ja)
|
2012-07-06 |
2016-02-10 |
東京エレクトロン株式会社 |
成膜装置の運転方法及び成膜装置
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
US9944689B2
(en)
|
2013-03-07 |
2018-04-17 |
The General Hospital Corporation |
Human CTLA4 mutants and use thereof
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
HK1219740A1
(zh)
|
2013-03-15 |
2017-04-13 |
Biogen Ma Inc. |
使用抗αVβ5抗体治疗和预防急性肾损伤
|
|
WO2014198002A1
(en)
|
2013-06-14 |
2014-12-18 |
Ottawa Hospital Research Institute |
A bacterium producing an interferon binding protein and uses thereof
|
|
GB201311475D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Polypeptides
|
|
CN110511960B
(zh)
|
2013-07-15 |
2023-05-23 |
美国卫生和人力服务部 |
抗人乳头瘤病毒16 e6 t细胞受体
|
|
WO2015103438A2
(en)
|
2014-01-02 |
2015-07-09 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
|
RU2727639C2
(ru)
|
2014-01-15 |
2020-07-22 |
Ф.Хоффманн-Ля Рош Аг |
Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
|
|
KR20150135148A
(ko)
|
2014-05-23 |
2015-12-02 |
주식회사 제넥신 |
Pd-l1 융합 단백질 및 이의 용도
|
|
IL290655B2
(en)
|
2014-05-29 |
2024-05-01 |
Us Health |
Anti-human papillomavirus 16 E7 T-cell chelates
|
|
EP3169352A1
(en)
|
2014-07-15 |
2017-05-24 |
Immune Design Corp. |
Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
|
|
US9546206B2
(en)
|
2014-08-08 |
2017-01-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
High affinity PD-1 agents and methods of use
|
|
EP3188752A2
(en)
|
2014-09-03 |
2017-07-12 |
Bavarian Nordic A/S |
Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
|
|
CN107207597A
(zh)
|
2014-11-06 |
2017-09-26 |
儿研所儿童医学中心 |
用于癌症和自身免疫疾病的免疫疗法
|
|
EP3020816A1
(en)
|
2014-11-11 |
2016-05-18 |
University College Cork |
Bacterial mediated gene therapy
|
|
WO2016118577A1
(en)
|
2015-01-22 |
2016-07-28 |
Medimmune, Llc |
Thymosin-beta-four fusion proteins
|
|
WO2016164428A1
(en)
|
2015-04-06 |
2016-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
|
|
EP3283508B1
(en)
|
2015-04-17 |
2021-03-17 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins with tunable affinities
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
TN2019000101A1
(en)
|
2015-05-29 |
2020-07-15 |
Bristol Myers Squibb Co |
Antibodies against ox40 and uses thereof.
|
|
WO2017019846A1
(en)
|
2015-07-30 |
2017-02-02 |
Macrogenics, Inc. |
Pd-1-binding molecules and methods use thereof
|
|
WO2017029389A1
(en)
|
2015-08-20 |
2017-02-23 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
B7-h1 fusion polypeptides for treating and preventing organ failure
|
|
JP2018534245A
(ja)
|
2015-09-14 |
2018-11-22 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
調整可能なバリアント免疫グロブリンスーパーファミリードメインおよび改変細胞療法
|
|
PL3368572T3
(pl)
|
2015-10-02 |
2022-09-12 |
Symphogen A/S |
Przeciwciała anty-PD-1 oraz kompozycje
|
|
AU2016350701B2
(en)
|
2015-11-02 |
2021-08-19 |
Five Prime Therapeutics, Inc. |
CD80 extracellular domain polypeptides and their use in cancer treatment
|
|
JP7148399B2
(ja)
|
2015-11-04 |
2022-10-05 |
タイペイ・ベテランズ・ジェネラル・ホスピタル |
悪性疾患に対する併用療法
|
|
US10954301B2
(en)
|
2015-12-14 |
2021-03-23 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
|
|
IL262365B2
(en)
|
2016-04-15 |
2024-11-01 |
Alpine Immune Sciences Inc |
Immunomodulatory proteins ICOS ligand variants and uses thereof
|
|
EP4706777A2
(en)
|
2016-04-15 |
2026-03-11 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
KR20190044029A
(ko)
|
2016-05-18 |
2019-04-29 |
알버트 아인슈타인 컬리지 오브 메디슨, 인크. |
변이체 pd-l1 폴리펩타이드, t-세포 조절 다량체 폴리펩타이드 및 이들의 사용 방법
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
|
CN110088127A
(zh)
|
2016-07-28 |
2019-08-02 |
高山免疫科学股份有限公司 |
Cd155变体免疫调节蛋白及其用途
|
|
CN110214147A
(zh)
|
2016-10-14 |
2019-09-06 |
Xencor股份有限公司 |
IL15/IL15Rα异源二聚体FC-融合蛋白
|
|
CA3040296A1
(en)
|
2016-10-20 |
2018-04-26 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
EP3596114A2
(en)
|
2017-03-16 |
2020-01-22 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
PT3596116T
(pt)
|
2017-03-16 |
2023-12-04 |
Alpine Immune Sciences Inc |
Proteínas imunomoduladoras de pd-l1 variante e suas utilizações
|
|
KR102813968B1
(ko)
|
2017-10-10 |
2025-05-29 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Ctla-4 변이체 면역조절 단백질 및 이의 용도
|
|
SG11202006148UA
(en)
|
2018-01-03 |
2020-07-29 |
Alpine Immune Sciences Inc |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
US12065476B2
(en)
*
|
2018-06-15 |
2024-08-20 |
Alpine Immune Sciences, Inc. |
PD-1 variant immunomodulatory proteins and uses thereof
|